STING1 and neoplasm: Intravenous administration of 10 μg doses of cGAMP encapsulated in STING-NPs preferentially accumulated in the diseased hindlimb and reduced tumor burden at day 7 and decreased bone destruction at days 7 and 14 (Fig. 1C–H, 2A–G).